High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Surgical staging for penile cancer in Zambia finds 37.5% metastasis yield in palpable nodes
Study in Zambia finds surgical lymph node staging for penile cancer has modest yield
A prospective cross-sectional cohort study of 40 patients with invasive penile squamous cell carcinoma in Zambia (87.5% HIV seropositive) fo…
In Zambia, many swollen groin nodes in penile cancer patients do not contain cancer, suggesting less invasive tests might avoid unnecessary …
Research across Cancer
Related studies from across the Cancer family.
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC
Doctors are shifting from static staging to adaptive care for HPV throat cancer
This narrative review discusses the evolving management of HPV-associated oropharyngeal squamous cell carcinoma. The authors argue for trans…
Medical teams are moving away from old staging rules toward a new model that uses genomics and immunology for precise care.
Narrative review discusses HPV-associated head and neck and cervical squamous cell carcinoma without reporting specific outcomes
Doctors Find Hidden Pattern in HPV Cancers That Changes Treatment
This narrative review addresses patients with HPV-associated tumors involving head and neck squamous cell carcinoma and squamous cell carcin…
HPV cancers in the head and neck hide from the immune system differently than cervical cancers, explaining why some patients respond better …
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation
Low blood counts and high inflammation may signal worse survival for anal cancer patients
This systematic review and meta-analysis of 3589 patients with anal squamous cell carcinoma found that elevated neutrophil-to-lymphocyte rat…
For patients with anal cancer, low hemoglobin and high inflammation markers linked to poorer survival in this analysis of nearly 3,600 peopl…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma
Rare case: child dies 7 months after esophageal cancer diagnosis
This case report and retrospective literature analysis describes a 10 year old male with lower esophageal squamous cell carcinoma.
A 10-year-old with a rare esophageal cancer died 7 months after diagnosis, highlighting the urgent need for better treatments.
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Review of case report showing durable response after surgery in metastatic bladder SqCC
She Was Offered Hospice. Surgery Gave Her Two More Years Instead
This narrative review synthesizes a single case report of a 65-year-old woman with metastatic squamous cell carcinoma of the bladder.
A woman with a rare, drug-resistant bladder cancer that had spread to both lungs chose surgery when hospice was offered — and two years late…
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Cadonilimab therapy in cervical cancer associated with new-onset type 1 diabetes and diabetic ketoacidosis in a case report
A Cancer Drug Triggered Sudden Diabetes in an 81-Year-Old
This systematic review includes a case report of an 81-year-old female with cervical squamous cell carcinoma who developed diabetic ketoacid…
A powerful cancer drug can switch off the body's insulin supply almost overnight, causing sudden, life-threatening diabetes in patients with…
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…